Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
- Acquisition of a technology developed by Occlugel, a French company specialized in the R&D of microspheres used in embolization;
- This new technology will round out Guerbet's Interventional Imaging solutions and create synergies with the Accurate range of anti-reflux microcatheters.
Villepinte (France), April 26, 2018 (18:00 CEST) - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announced today that it has signed an agreement to acquire a laboratory-stage technology developed by Occlugel, a French company specialized in the R&D of microspheres used in embolization.
This acquisition is line with the GEAR 2023 strategic plan, and is one of two acquisitions planned by the end of this financial year.
"We are very pleased to integrate this new microsphere technology into our Interventional Imaging R&D program", said Claire Corot, Research, Innovation & Business Development VP.
Under the terms of the agreement and in exchange for the acquisition of this technology, Guerbet has made an initial payment of €3 million, with additional payments conditional on completing the technology transfer and achieving regulatory objectives.
A complementary technology for Interventional Imaging
The technology will be used in several ranges of microspheres for vascular embolization of benign tumors, for example uterine fibroma and prostate adenoma, and for vascular chemoembolization of malignant tumors, including in some liver, lung and kidney cancers.
This technology will complete the existing range of Guerbet's Interventional Imaging solutions, and above all create strong synergies with the Accurate range of anti-reflux microcatheters, acquired recently by Guerbet.
About Guerbet
Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 7% of revenue dedicated to R&D and more than 200 employees distributed amongst its three centers in France and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B - mid caps) and generated €807 million in revenue in 2017. For more information about Guerbet, please visit www.guerbet.com
Media Relations
| Guerbet Global Alize RP Caroline Carmagnol and Wendy Rigal +33 (0)1 44 54 36 66 / +33 (0)6 48 82 18 94 [email protected] | |
Attachment
